Agonist News and Research

RSS

Activation of PPARβ/δ-AMPK pathway shown to slow liver fibrosis development

A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre (CIBERDEM) at the University of Barcelona, reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic dysfunction-associated steatotic liver disease).

17 Sep 2024

Review highlights mitochondrial dysfunction in cholestatic liver injury

Bile acids are essential signaling molecules derived from cholesterol metabolism in the liver and are crucial for the digestion and absorption of fats.

16 Sep 2024

Cannabidiol shows promise in treating cognitive disorders

Research reviews the therapeutic potential of cannabidiol (CBD) in treating cognitive impairments, highlighting positive effects in some trials while emphasizing the need for more comprehensive studies.

12 Sep 2024

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged.

12 Sep 2024

Women experience greater weight loss with tirzepatide compared to men

All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced greater weight loss, according to new post hoc research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

11 Sep 2024

Obesity medication liraglutide safe and effective in children under 12, research finds

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), and published simultaneously in the New England Journal of Medicine (NEJM), has found.

10 Sep 2024

Once-a-day oral weight loss drug shows promising results in reducing body weight

Individuals who received a once-a-day oral weight loss drug lost up to 13% of their body weight over three months, the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear.

10 Sep 2024

GLP-1 receptor agonists show promise in treating substance use disorders

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.

9 Sep 2024

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year's annual meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

9 Sep 2024

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

2 Sep 2024

North Carolina's residential opioid treatment services lack evidence-based approaches

A new study of organizations that claim to provide residential opioid substance use services in North Carolina found that only 12% of the organizations were licensed by the state to provide residential substance use treatment. What's more, only about a quarter of the organizations even allowed patients to access the only treatment for opioid use disorder proven to reduce overdose deaths.

29 Aug 2024

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

A study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with or without existing diabetes, while also achieving greater weight loss.

28 Aug 2024

Researchers demonstrate a new method to combat pancreatic cancer

Researchers at the University of Massachusetts Amherst and UMass Chan Medical School have demonstrated in mice a new method to combat pancreatic cancer.

28 Aug 2024

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Semaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.

27 Aug 2024

Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

If Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible while new federal spending could still exceed $10 billion

27 Aug 2024

How diet shapes gut microbiota and affects brain function

Researchers discuss the diet-microbiota-gut-brain axis, which describes the role of both diet and gut microbiota composition on cognitive and emotional health.

26 Aug 2024

GLP-1 therapy boosts visceral fat metabolism, driving weight loss

Researchers discuss the role of enhanced visceral adipose tissue metabolism in mediating weight loss by glucagon-like peptide-1 drugs.

26 Aug 2024

Gut microbe metabolite found to modulate heart disease risk through β2-adrenergic receptors

Study identifies phenylacetylglutamine (PAGln), a gut microbiome metabolite, as a novel allosteric modulator of β2-adrenergic receptors, offering insights into its role in cardiovascular disease (CVD) risk.

26 Aug 2024

Unique strain of probiotic bacteria shows potential in combating inflammatory diseases

23 Aug 2024

Probiotic offers protection against intestinal damage

There is a critical unmet need to help tighten and maintain a healthy intestinal barrier and treat a leaky gut. Researchers have now found that a unique strain of probiotic bacteria, Bifidobacterium bifidum BB1, enhances intestinal barrier function and protects against penetration of bacteria and various harmful agents in the intestine. The findings, detailed in an article in The American Journal of Pathology, published by Elsevier, can help advance the development of novel, targeted, naturally occurring probiotic therapy for patients with inflammatory bowel disease (IBD) and other inflammatory diseases, such as fatty liver disease or alcoholic liver disease, that are associated with a leaky or disordered intestinal barrier.

23 Aug 2024

Agonist News and Research

Activation of PPARβ/δ-AMPK pathway shown to slow liver fibrosis development

Review highlights mitochondrial dysfunction in cholestatic liver injury

Cannabidiol shows promise in treating cognitive disorders

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

Women experience greater weight loss with tirzepatide compared to men

Obesity medication liraglutide safe and effective in children under 12, research finds

Once-a-day oral weight loss drug shows promising results in reducing body weight

GLP-1 receptor agonists show promise in treating substance use disorders

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

North Carolina's residential opioid treatment services lack evidence-based approaches

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

Researchers demonstrate a new method to combat pancreatic cancer

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

How diet shapes gut microbiota and affects brain function

GLP-1 therapy boosts visceral fat metabolism, driving weight loss

Gut microbe metabolite found to modulate heart disease risk through β2-adrenergic receptors

Unique strain of probiotic bacteria shows potential in combating inflammatory diseases

Probiotic offers protection against intestinal damage

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News